Late-breaker on clinical trials: less is more, but not always.

This years’ late-breaker session on clinical trials at ECCMID had 8 presentations; 3 on shortening duration of treatment; 2 compared antibiotics; 2 phase PK/PD studies and 1 PK/PD study in kids. The room was packed (and not that big anyway), so you may be interested to read what I thought I heard (and saw).

Dafna Yahav presented 7 vs 14 days for GNB BSI (community- and hospital-acquitred), an open-label non-inferiority RCT in 3 centers (2 in Israel and 1 in Italy). They adopted a non-inferiority margin of 10%, and pursued a sample size of 2×300 patients. Patients with GNB BSI that were afebrile and haemodynamically stable before day 5, could be randomzied. The priary outcome was a composite of all cause mortality, clinical failure and readmission/extended stay at day 90. They had 306 patients in the 7 days group and 298 in 14 days, with a balanced baseline table; 25% of infections was hospital-acquired; 70% had UTI, 65% were E. coli. The primary endpoint was reached in 141/306 and 149/298 patients yielding an absolute Risk Difference (aRD) of -3.9% (95% CI -11.9-4%), with non-inferiority demonstrated. 7 days was associated with less antibiotic use and earlier recovery. Conclusion: safe to stop at day 7 in non-neutropenic, HD stable patients not having an uncontrolled source infection that had a GNB BSI.

Duncan Cranendonk presented the DANCE trial comparing 6 days to 12 days of antibiotic treatment for severe cellulitis; all started with flucloxacillin (Dutch study, no MRSA) and were randomized at day 5-6 to placebo or continuation of antibiotics. The primary endpoint was clinical cure at  day 14. In all, 151 patients were randomized; 74 to 6 days 77 to 12 days, and 69 and 71 were evaluable in the modified Intention To Treat (mITT). The groups were well balanced, and the clinical cure rate was about 50% in both groups, with and aRD of 1.4% (95% CI 14.8-17.5%). So, the the non-inferiority margin of 10% was crossed. Moreover, relapses occurred more frequently in the 6-day group. Thus: non-inferiority not demonstrated (which may have resulted from not reaching the pursued enrollment) and more relapses….. So, keep on finalzing your 12-day course of antibiotics, is their message.

Aurelien Dinh presented the effectivenes of 3 days (vs 8 days) of beta-lactam antibiotics for hospitalized community-acquired pneumonia (CAP): a randomized non-inferiority double-blind trial. Fresh from the press, with last data from last Friday. The study domain included patients with “non-ICU CAP” treated with either amoxi-clav or 3rd generation cephalosporin and clinically stable at day 3. Dual therapy was not allowed (only 1 dose of macrolide or quinolone was). Randomization occurred at day 3, to placebo or oral amoxi clav. The primary endpoint was clinial cure (absence of fever, absence/improvement of clinica symptims, no new antibiotics ater day 3) at day 15. In the ITT they had 152 (8 days) and 156 patients (3 days), well balanced, median PSI 81-84, 4% had bacteremia, and 5% had a positive urinary pneumococcal antigen test. The primary endpoint was reached in 69.9% of patients in the 3-day group and in 61.2% in the 8-day group, yielding a 95% CI ranging from -1.09% to 20.55%, clearly demonstrating non-inferiority. One attendee in the audience not suffering from the oxygen-deficit had calculated that on average each participating hospital had included 3 patients per year, and whatt that meant for generalizibility.

Patrick Harris presented the MERINO trial in which piperacillin-tazobactam was compared to meropenem for definite treatment of BSI caused by 3rdG-Ceph-non-susceptible GNB (mainly E. coli). The primary endpoint was day-30 mortality. Patients needed to be enrolled within 72 hours after the index blood culture and had to receive at least 5 days of antibiotics. In all 391 patients were randomized and 378 evaluable; 85% of infections caused by E. coli, 45% community-were acquired. The study was suspened ath 3rd preplanned interim-analysis as it was highly unlikely that non-inferiority could be demonstrated, For day-30 mortality the aRD was 8.6% (95% CI 3.4-14.5), yielding a number needed to harm of 12! All secondary endpoinits favored meropenem. So, what started as a trial to reduce carbapenem use, provided undisputable evidence to do the opposite.

Finally, Angela Huttner presented a study from the AIDA project, which aimed to preserve old antibiotics for the future. in this open-label/analyst-blinded RCT, non-pregnant women aged ≥18 years with symptoms of lower UTI, a positive urine dipstick and no known colonization or previous infection with uropathogens resistant to the study antibiotics were included in Switzerland, Poland, and Israel. Women were randomized to either nitrofurantoine (5 days) (n=255) or a single-dose of fosfomycin (3 gram) (n=258). The primary outcome was clinical response at 28 days after therapy completion, defined as cure (complete resolution of symptoms and signs of UTI), failure (need for additional or change in antibiotic treatment due to UTI, or discontinuation due to lack of efficacy), or indeterminate (persistence of symptoms without objective evidence of infection). Both clinical and microbiological cure at day 28 was achieved more frequently in patients receiving nitrofurantoin (70% vs 58%; p=0.016; 74% vs 63%; p=0.037), as was hypothesized by the investigators. For those patients with E. coli infection the difference was even larger (aRD of 28%). So, the old drug (fosfo when used as a single-dose treatment) was worse than what is currently used in most countries for this indication. The study was published online in JAMA during the late-breaker session.

Five excellent investigator-initiated studies, that may all change our treatment guidelines. Unfortunately, short, old and less broad-spectrum is not always the better choice. Hope that many young scientists get inspired and will not be stopped by upcoming new EU regulations for clinical trials, see.

Advertisements

The reality of AMR in Greece

This week I attend the general assembly of COMBACTE, this year in Athens. COMBACTE stands for COMBatting AntibiotiC resistance in Europe (www.combacte.com) and is part of the New Drugs for Bad Bugs (ND4BB) program of the Innovative Medicines Initiative. Our local host is professor George Daikos, who opened the meeting with an overview of the epidemiology of antibiotic resistance in his country. Continue reading

How to predict ESBL (part 5)

A brief update on the ESBL predict study, after the last update  from 6 months ago. Tim Deelen from our group is still running the show and we are still seeking hospitals for participation. It’s for free, it’s easy, relevant and fun! We passed the 5,500 episodes and we learn a lot, including how countries deal with the ethical aspects of this study. Continue reading

What’s up for 2018?

I hope you enjoyed Christmas time and wish you all the best for this year. From my side, I will continue to reflect what I meet professionally, what surprises me, confirms what I thought to know or what confirms my ignorance. In 2017 I did that 41 times (a surprise to me!) and here are some trending topics that will most likely return in 2018. Continue reading

What about E. coli ST131?

One of the faces of the global antibiotic resistance crisis is Escherichia coli ST131, frequently portrayed as a pandemic clone, combining hypervirulence, ciprofloxacin resistance and ESBL production. A recent study in Genome Research, a journal you may not read every month, though, sheds a whole new light on this “superbug”. Continue reading

The antibiotic resistance crisis resolved by bacteriophages (part 2)

Earlier this week I blogged on the potential (yet poorly proven) effects of bacteriophages as salvage therapy for infections caused by AMR, and stated: “Phages and their active enzymes are proteins that evoke an immunological host response when injected, and up till now all attempts to circumvene those unwanted effects have failed.” Two recent case reports challenge part of that statement. Continue reading

How to predict ESBL (part 4)

Two months ago I provided an update on the ESBL-predict study that Tim Deelen from our group coordinates. In short: Every hospital in the world can participate, through a user-friendly electronic CRF (in a secured environment), in the validation of 2 scoring systems to predict that sepsis is caused by ESBL-producing bacteria. Only relevant for those of us that are not yet ready to start meropenem/amikacine for every patient that starts with antibiotics! This tool may help, …. if reliable. We passed the 3,000 episodes! Here is a short update and info for those that want to join. Continue reading